Dr Strahlman brings to the Board C-suite executive experience at multiple global healthcare companies. She is passionate about innovation that transforms and democratizes technology into products that help people, with an accompanying track record of delivering value to business through her philosophy of Servant Leadership.
Dr. Strahlman served as Executive Vice President, Research & Development and Chief Medical Officer of Becton, Dickinson and Company (NYSE:BDX), a leading global medical technology company, from 2013 until her retirement in 2018. While at BD, the company was selected as the Outstanding Corporate Innovator in 2015 by the Product Development & Management Association. Before joining BD, she served as Senior Vice President and Chief Medical Officer for GlaxoSmithKline, plc (NYSE:GSK) from 2008 to 2013, spending her last year at GSK as Senior Advisor to the CEO, leading GSK’s Global Health Programs. Prior to 2008, Dr. Strahlman held senior executive leadership roles in global product development and commercialization and business development at Pfizer, Inc. (NYSE:PFE), Novartis AG (NYSE:NVS), Virogen Limited, and Merck & Co., Inc (NYSE: MRK). She was the Senior Vice President for Research & Development and Chief Medical Officer for Bausch & Lomb (NYSE:BLCO ) from 1995-2000.
Dr Strahlman was chosen to serve as Industry Representative on the FDA/CDER Dermatology and Ophthalmology Advisory Committee (DODAC), from 2008-2013. From 2016 to November 2020, Dr. Strahlman served as a director of Syncona Limited (NYSE: SYN.L), having previously served as a director of Syncona Partners, LLP. She is currently a director of Altria Group, Inc. (NYSE:MO). In addition to her corporate board service, Dr Strahlman serves as Visiting Professor, University of Turku, in Finland.
Dr Strahlman earned a BA from Harvard University in biochemistry and an MD from the Johns Hopkins School of Medicine. She is an American Board of Ophthalmology (ABO) board-certified ophthalmologist, having trained at the Wilmer Eye Institute from 1984-1987. She was awarded a Carnegie Mellon Public Health Fellowship in 1987, during which she earned an MHSc in Epidemiology from the Bloomberg School of Public Health (1987-1989).
What is Ellen R. Strahlman's net worth?
The estimated net worth of Ellen R. Strahlman is at least $101.46 thousand as of May 26th, 2026. Dr. Strahlman owns 25,102 shares of Hyperion DeFi stock worth more than $101,462 as of September 22nd. This net worth evaluation does not reflect any other assets that Dr. Strahlman may own. Learn More about Ellen R. Strahlman's net worth.
How do I contact Ellen R. Strahlman?
Has Ellen R. Strahlman been buying or selling shares of Hyperion DeFi?
Ellen R. Strahlman has not been actively trading shares of Hyperion DeFi within the last three months. Most recently, on Monday, December 29th, Ellen R. Strahlman bought 12,112 shares of Hyperion DeFi stock. The stock was acquired at an average cost of $3.60 per share, with a total value of $43,603.20. Following the completion of the transaction, the director now directly owns 91,161 shares of the company's stock, valued at $328,179.60. Learn More on Ellen R. Strahlman's trading history.
Who are Hyperion DeFi's active insiders?
Are insiders buying or selling shares of Hyperion DeFi?
In the last twelve months, Hyperion DeFi insiders bought shares 11 times. They purchased a total of 197,204 shares worth more than $641,026.94. The most recent insider tranaction occured on June, 2nd when insider Hyunsu Jung bought 1,000 shares worth more than $3,660.00. Insiders at Hyperion DeFi own 7.5% of the company.
Learn More about insider trades at Hyperion DeFi. Information on this page was last updated on 6/2/2026.
